Comparative performance of human papillomavirus messenger RNA versus DNA screening tests at baseline and 48 months in the HPV FOCAL trial

There was no significant difference in CIN2+ detection for AHPV vs. HC2 at baseline or at 48 mo. Baseline AHPV− and HC2− women had similar CIN2+ rates at 48 mo., demonstrating the safety of a four year screening interval for AHPV− women.